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ABSTRACT
High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation is a widely applied
treatment for advanced non-Hodgkin lymphoma (NHL), but few studies have analyzed the tolerability and out-
comes in older patients compared with younger patients treated in a homogeneous manner. We retrospectively
reviewed 152 consecutive patients who underwent autologous stem cell transplantation (ASCT) following
BEAM conditioning (carmustine, etoposide, cytarabine, and melphalan) for NHL from January 2000 through
August 2004 at our institution. We compared 59 patients age$60 years and 93 patients age\60 years. Support-
ive care was identical for all patients. The frequency of comorbidities was similar between both groups. CD341
cell doses, days to neutrophil recovery, and days to platelet count .20,000/mm3 were similar in younger and
older patients, although days to platelet count .50,000/mm3 were longer in the older patients (median 30.0
days versus 22.5 days, P 5 .01). Patients over the age of 60 were more likely to develop grade III/IV mucositis
than their younger counterparts (37.7% versus17.4%, P 5 .0063). Otherwise, the frequency of other grade
III/IV toxicities were similar between younger and older patients. Treatment-related mortality (TRM) was sim-
ilar between older and younger patients (8.5% versus 5.4%,P5 .45). Although agewas not associatedwithTRM,
the Charlson Comorbidity Index Score was significantly correlated with TRM (P 5 .03). Median disease-free
survival was similar between older and younger patients (21.8months versus 29.9months, P5 .93), as was overall
survival (OS) (47.7 months versus 62.5 months, P 5 .20). After controlling for age, the Charlson Comorbidity
Index Score influenced OS [P 5 .013]. Overall, our cohort of patients with NHL over the age of 60 who under-
went ASCT following BEAM conditioning experienced toxicities and survival similar to their younger counter-
parts. Comorbidities significantly influenced TRM and OS in this retrospective cohort. Future study should
focus on improving tolerability of conditioning and careful prospective evaluation of comorbidities and their
association with outcomes.
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Although autologous stem cell transplantation
(ASCT) following high-dose chemotherapy is a widely
utilized strategy for relapsed non-Hodgkin lymphoma
(NHL), few studies have examined the tolerability and
efficacy in patients over the age of 60. Prior studies ex-
amining the use of autologous transplant in the elderly
are limited in their current applicability by small sam-
ple size, the use of bone marrow rather than mobilized840peripheral blood stem cells, inclusion of multiple un-
derlying malignancies, and an array of conditioning
regimens. Early studies of autologous bone marrow
transplants in older patients found transplant-related
mortality rates as high as 28% in patients over the
age of 50 [1], or even as high as 60% in a cohort of
patients over the age of 55 who received total-body
irradiation (TBI) [2]. More recent studies evaluating
only peripheral blood stem cell transplants have found
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of 60 [3-13]). Some studies have shown higher rates of
mucositis [11], infectious complications [14], and
cardiac toxicity [13] in older patients. Overall, the tol-
erability and efficacy of high-dose chemotherapy
(HDT) and ASCT for NHL in patients over 60 has
not been well characterized. We therefore undertook
a retrospective review of all patients who underwent
ASCT for NHL following an identical BEAM condi-
tioning and supportive care strategy between January
2000 and August 2004.
METHODS
With the approval of the institutional review
board, we retrospectively identified 152 consecutive
patients who underwent ASCT for NHL at a single
institution following BEAM conditioning between
January 1, 2000 and August 31, 2004 from the Wash-
ington University School of Medicine Bone Marrow
Transplant database.
All patients underwent peripheral blood stem cell
harvest via tunneled pheresis catheter following cyto-
kine or chemomobilization. The goal number of
CD341 cells collected was 2.5  106 cells/kg. The
pheresis laboratory database provided data regarding
stem cell mobilization. Conditioning for all patients
consisted of: carmustine 450 mg/m2 until April 2003
(97 patients), at which time the institutional protocol
was changed, and the carmustine dose was decreased
to 300 mg/m2 (55 patients) on day 28, etoposide 100
mg/m2 every 12 hours (total 200 mg/m2/day) on day
27 through day 24, cytarabine 100 mg/m2 every
12 hours (total 200 mg/m2/day) on day 27 through
day 24, and melphalan 140 mg/m2 on day 23, fol-
lowed by 2 rest days. On the day of transplant, cryopre-
served stem cell products were warmed to 37C and
infused per protocol. Patients received growth factor
support with colony stimulating factors and other sup-
portive care per institutional standards.
The medical records were reviewed for laboratory
results and comorbid medical conditions. Toxicities
were graded retrospectively using the NCI Common
Toxicity Criteria v3.0. Days to neutrophil recovery
(absolute neutrophil count [ANC] .500/mm3) and
platelet recovery (platelet count .20,000/mm3 and
50,000/mm3, without transfusion) were calculated
from date of transplant. If the patient survived to neu-
trophil recovery, days of neutropenic fevers were cal-
culated from date of transplant. All Gram-negative
bacteremias and fungemias were considered patho-
genic. When nonpathogenic Gram-positive bacteria
were cultured, they were considered pathogenic if
more than 1 blood culture was positive. Creatinine
clearance was calculated using the Cockcroft-Gault
method [15], and the serum creatinine, weight, and
height at the time of initiation of conditioning; whereideal body weight and actual body weight differed sig-
nificantly, the lower estimated creatinine clearance was
utilized. The Charlson Comorbidity Index (CCI)
[16,17] was calculated from known medical history at
the time of admission for stem cell transplant, inclusive
of the diagnosis of NHL.
Disease-free survival (DFS) was defined as the time
from transplant to recurrence or death from any cause.
Overall survival (OS) was defined as the time from
transplant to death from any cause. Treatment-related
mortality (TRM) was defined as death unrelated to re-
lapse within the first 100 days following autologous
stem cell transplant.
Statistical Analysis
DFS and OS rates were estimated by the Kaplan-
Meier method. The log-rank test was used to examine
potential differences in survival between age groups.
In addition, multivariate Cox proportional hazards
models were fitted to test independent effects after con-
trolling for confounding covariates.Other statistical ap-
proaches used for the analyses included Student’s t-test,
Wilcoxon nonparametric test, c2 test, Fisher’s exact
text, and Pearson or Spearman correlation test. The sig-
nificance level used in the study was 0.05, and all tests
were 2-sided. All statistical analyses were performed
using SAS version 9.1 (SAS Institute Inc, Cary, NC).
RESULTS
Baseline Characteristics
A total of 152 consecutive patients from a single in-
stitution were included; 59 were age 60 or older (mean
age 64.16 3.4, range: 60-73) and 93 were under age 60
(48.66 9.0, range: 21-59). In the older group, 42% of
the patients were female, whereas 47% of the patients
in the younger group were female. The mean CCI was
similar between the 2 groups (2.6 6 0.8 in the older
patients, 2.4 6 0.7 in the younger patients, P 5 .10).
Table 1 details the baseline demographics, histology,
and treatment history of the patients.
Mobilization
The number of pheresis sessions, number of stem
cell products collected, and total CD341 counts did
not differ between older and younger patients (Table 2).
Similar numbers of patients underwent mobilization
with cytokines only (89.8% in older patients versus
95.7% in younger, P 5 .15); the remainder either
underwent chemotherapy-induced mobilization, cy-
tokines in combination with chemotherapy, or
others.
Engraftment
Overall, the older and younger cohorts had similar
engraftment kinetics, with the exception of platelet re-
covery. Older patients required a mean of 12.7 6 5.5
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Age $60 Years Age\60 Years P Value
Number of patients 59 93
Mean age in years: mean ± standard deviation (range) 64.1 ± 3.4 (60-73) 48.6 ± 9.0 (21-59)
Gender: frequency (percent) ..1
Female 25 (42%) 44 (47%)
Male 34 (58%) 49 (53%)
Histology: frequency (percent) ..1
Diffuse large B cell 36/59 (61%) 44/93(47%)
Follicular lymphoma 15/59 (25%) 26/93 (28%)
Mantle cell lymphoma 6/59 (10.2%) 6/93 (6.5%)
Anaplastic large cell lymphoma 1/59 (1.7%) 5/93 (5.4%)
Peripheral T cell lymphomas 1/59 (1.7%) 7/93 (7.5%)
Other high grade 0/59 (0%) 5/93 (5.4%)
Mean Charlson Comorbidity Index Score 2.6 ± 0.8 2.4 ± 0.7 .10
Number of pretranspant chemotherapy regimens: mean (range) 2.2 (1-4) 1.9 (1-3) .005
Prior fludarabine: frequency (percent) 4/59 (6.8%) 7/93 (7.5%) ..1
Chemosensitive at transplant: frequency (percent) 54/59 (91.5%) 88/93 (94.6%) ..1
Prior rituximab (in patients with B cell lymphomas): frequency (percent) 47/57 (82%) 55/79 (70%) ..1
Prior radiation therapy 11/59 (18.6%) 16/93 (17.2%) ..1days (range: 9-39) to achieve an absolute neutrophil
count .500/mm3, whereas younger patients required
12.56 4.1 days (range: 9-38) (P5 .81). Days to achiev-
ing a platelet count of .20,000/mm3 independent of
transfusion were similar between the 2 groups (median
21.5 days [range: 7-219] in older patients versus 15.5
days [range 6-463] in younger patients, P5 .69). How-
ever, the older patient required a significantly longer
time to recovery of platelet count to .50,000/mm3
(median 30.0 days [range: 13-561] versus 22.5 days in
younger patients [range 12-104], P 5 .01).
Only 1 patient failed to recover his ANC and died
on posttransplant day 45; he was in the younger
cohort. Of the patients in the older cohort, 5.1% failed
to recover their platelet count to.20,000/mm3, com-
pared to 5.4% in the younger cohort (P5 .94). Of the
older patients, 10.2% failed to recover their platelet to
.50,000/mm3, compared to 11.8% of the younger pa-
tients (P5 .75). Changes in carmustine dose instituted
during the study period did not affect engraftment
(data not shown).
Infectious Complications
The older and younger patients had similar rates of
infectious complications during the posttransplant
period. Older patients had a mean of 5.3 6 2.6 days
(range: 1-13) of neutropenic fevers, whereas younger
patients averaged 4.9 6 3.1 days (range: 0-19) (P 5.38). Overall rates of documented bacteremia were
similar (35.6% in older patients versus 24.7% in youn-
ger patients, P 5 .15), as were rates of Gram-negative
bacteremia (20.3% in older patients versus 12.9% in
younger patients, P 5 .22) and Gram-positive bacter-
emia (16.9% in older patients versus 12.9% in youn-
ger, P 5 .49). Duration of intravenous antibiotic use
was similar between older and younger patients (14.3
6 6.5 days [range: 6-38] versus 14.4 6 9.2 [range:
0-66], P 5 .92). Rates of documented fungemia
(10.2% in older patients versus 4.3% in younger pa-
tients, P 5 .15) and days of intravenous antifungal
use (6.7 6 7.0 days [range: 0-31] versus 6.6 6 9.8
days [range: 0-67], P 5 .94) were statistically similar
in each group. The incidence of Clostridium difficile-
associated diarrhea was similar between the older and
younger patients (16.9% versus 11.8%, P 5 .37).
TRM and Morbidity
TRM was similar between older and younger pa-
tients (8.5% versus 5.4%, P 5 .45). Although age
.60 or \60 was not significantly associated with
TRM, the score on the CCI significantly correlated
with TRM (r 5 0.17, P 5 0.03).
Severe oral mucositis (OM) was more common in
the older patients; a significantly larger proportion of
older patients had $grade 3 OM (33.9% of patients
$60 years versus 17.2% of patients\60 years, P 5Table 2. Peripheral Blood Stem Cell Harvest
Patients $60 Years
(Mean ± SD, Range)
Patients\60 Years
(Mean ± SD, Range) P
Pheresis sessions 1.4 ± 0.6 (1-4) 1.2 ± 0.5 (1-3) .16
CD341 cells  106/kg 3.5 ± 1.7 (1.7-10.6) 3.6 ± 1.8 (1.7-12.8) .68
Number of stem cell products 3.9 ± 2.6 (1-11) 3.4 ± 2.4 (1-11) .22
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All comparisons were not statistically significantly different unless noted.
Figure 1. Frequency of grade III/IV toxicities..0063). The severity of OM was significantly inversely
related with creatinine clearance (r 5 20.17, P 5
.045). The frequency of other grade III/IV toxicities
was similar between the 2 groups, detailed in Figure 1.
When toxicities were analyzed for association with the
CCI, there were no statistically significant correlations
between CCI and mucositis (r 5 0.039, P 5 .64),
nausea/vomiting (r 5 20.068, P 5 .41), diarrhea
(r 5 .034, P 5 .69), or incidence of bacteremia (r 5
0.11, P 5 .17).
Duration of hospitalization and rates of readmis-
sion did not differ between the older and younger pa-
tients. Older patients had a mean duration of
hospitalization from day of transplant of 16.2 6 5.6
days (range: 11-43), whereas younger patients stayed
in the hospital 17.2 6 8.4 days following transplant
(range: 10-56) (P 5 .45). Of the older patients 25.9%
were readmitted within the first 100 days for various
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Figure 2. DFS.complications, whereas 25.0% of the younger patients
required readmission (P 5 .90).
DFS and OS
Lactate dehydrogenase (LDH) immediately prior
to transplant did not predict risk of relapse (r 5
0.0011, P 5 .99). Aggressive versus indolent histology
influenced neither DFS (P 5 .85) nor OS (P 5 .18).
DFS was similar between older and younger patients
(Figure 2) (P 5 .94). In the older patients, the median
DFS was 21.8 months (95% Confidence Interval [CI]
10.5-43.3 months) versus 29.9 months (95% CI 21.8-
36.3 months) in the younger patients. OS was also
similar between patients over the age of 60 and those
younger than 60 (Figure 3) (P 5 .20). The median OS
in the older cohort was 47.7months versus 62.5months
in the younger patients. We then analyzed the relation-
ship between age as a continuous variable withDFS and
OS: Overall Survival
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Figure 3. OS.
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icant influence onDFS (P5 .40) or OS (P5 .059). After
controlling for age, comorbidity was an independent in-
fluential factor inbothOS(P5 .016) andDFS (P5 .036).
DISCUSSION
The present study demonstrates that autologous
stem cell transplant following BEAM conditioning
was efficacious and well tolerated in a cohort of
patients over the age of 60.
In this study, age alone did not predict TRM,DFS,
or OS in patients undergoing BEAM conditioning and
ASCT for relapsed NHL. Admittedly, the patients
who are eligible to proceed with HDT and ASCT
are a select population, with preserved performance
status and acceptable cardiac, pulmonary, hepatic,
and renal function. Our results will not be applicable
to patients who do not meet eligibility criteria to pro-
ceed with ASCT. In addition, a number of clinical pre-
dictors of outcome, including performance status and
the International Prognostic Index score could not be
reliably extracted from themedical record in this retro-
spective series. Differences in the histology of NHL
between the younger and older patients could also
have obscured differences in outcomes.
Despite these limitations in the applicability of our
findings, our results mirror what has been seen in the
literature addressing autologous transplant in the era
of peripheral blood stem cell transplant with improved
supportive care [11,13,18]. The influence of comor-
bidities on outcomes is receiving increasing attention.
The CCI score, as opposed to age, influenced TRM,
DFS, and OS in our study. A number of tools have
been developed for predicting the impact of comorbid-
ities on prognosis. The CCI [16,17], a weighted scale
based on the relative risk of death attributable to
a number of conditions, was utilized in this study given
the reliability with which it can be applied retrospec-
tively to a cohort. Monfardini et al. [19] created the
MACE scale (Multidimensional Assessment for Can-
cer in the Elderly), which incorporates a number of do-
mains including comorbidities, symptoms, cognition,
depression, physical function, and disability. A more
comprehensive assessment of comorbidity, the Cumu-
lative Illness Rating Scale-Geriatric (CIRS-G) [20],
rates the severity of illness and correlates well with
mortality, hospitalizations, and medication use [21].
However, when the CCI and CIRS-G were applied
to a geriatric oncology population, comorbidity corre-
lated poorly with functional status [22]. Because both
comorbidity and functional status independently pre-
dict survival in geriatric oncology patients [23], one
should not be used as a surrogate for the other. Unfor-
tunately, in this retrospective study, performance
status of the patients could not be reliably extracted
from the medical record to allow for analysis.Another recently developed comorbidity index, the
hematopoietic cell transplantation-specific comorbid-
ity index (HCT-CI) is more comprehensive in its
inclusion of comorbidities, and more tailored to co-
morbidities unique to the hematopoietic stem cell
transplantation population. It was initially developed
in allogeneic stem cell transplant patients [24]. In a re-
cent report, Sorror et al. [25] applied the HCT-CI to
a cohort of patients who had undergone ASCT for re-
lapsed lymphoma. The cohort included patients up to
age 76. On multivariate analysis, comorbidities inde-
pendently predicted nonrelapse mortality (NRM),
OS, and relapse-free survival (RFS).
Peripheral blood stem cell mobilization was simi-
lar between older and younger patients, with collection
of similar numbers of CD341 cells in similar numbers
of pheresis sessions. Although this study represents
a selected patient population who mobilized adequate
stem cell numbers to proceed with high-dose therapy,
previous studies have shown that elderlyNHLpatients
are able to mobilize and harvest peripheral blood stem
cells as successfully as their younger counterparts
[3,4,11,26]. Similarly, oldermultiplemyeloma patients
have been shown to mobilize peripheral blood stem
cells as successfully as younger patients [27].
Although neutrophil engraftment and platelet
count recovery to .20,000/mm3 was similar between
older and younger patients, there was a delay of plate-
let count recovery to .50,000/mm3 in older patients.
This is not explained by differences in stem cell harvest
or prior fludarabine exposure, as these were similar be-
tween the 2 groups. The patients in the older group
were more heavily pretreated, which could result in
damage to the bone marrow microenvironment and
the delay in platelet count recovery to .50,000/mm3
in older patients. An alternate explanation for this dif-
ference may be found in the increasing evidence that
aging affects the proliferative potential of hematopoi-
etic stem cells [28], which could explain age-related
differences in platelet recovery.
Overall, patients over the age of 60 tolerated
BEAM conditioning as well as their younger counter-
parts, with the exception of oral mucositis. Older
patients were more likely to experience grade III/IV
OM. This has been described previously [11]. Grade
of OM was significantly inversely correlated with
creatinine clearance (P5 .0448). This relationship be-
tween renal function and mucositis has been demon-
strated in other studies. A recent analysis of patients
with multiple myeloma undergoing ASCT explored
risk factors for oral mucositis [29]. The conditioning
regimen consisted of melphalan 200 mg/m2 as a single
dose, with reduction to 140 mg/m2 for patients with
creatinine .3 mg/dL. In that study, age did not inde-
pendently predict severe mucositis. On multivariate
logistic regression analysis, serum creatinine was sig-
nificantly associated with the development of severe
Comorbidities Impact Outcomes in ASCT 845mucositis (odds ratio 1.58 [CI 1.08-2.13]) [29]. Other
studies have similarly shown a relationship between
impaired renal function and severe mucositis in pa-
tients with myeloma receiving melphalan conditioning
for autologous stem cell transplant [30,31]. Although
melphalan is predominantly eliminated by spontane-
ous degradation, 13%-14% of melphalan is eliminated
by renal excretion [32]. It could be hypothesized that
increased drug exposure because of prolonged renal
excretion results in more severe mucositis. However,
a study of the pharmacokinetics of melphalan in the
setting of high dose therapy for multiple myeloma
concluded that creatinine clearance did not correlate
with plasma melphalan clearance or plasma AUC
[33]. Similar studies in the setting of combination
chemotherapy with BEAM have not been conducted.
Although melphalan likely plays the most significant
role in oral mucositis in the present study, cytarabine
and etoposide may also be contributory.
High-dose therapy with autologous peripheral
stem cell transplant remains the best chance for cure
in many patients with relapsed NHL. Future studies
could focus on improving the tolerability of high-
dose chemotherapy. Several interventions have been
utilized to decrease the incidence of mucositis. Cryo-
therapy has been successfully employed to reduce the
incidence of mucositis in multiple myeloma patients
receiving high-dose melphalan [34,35]. Amifostine
decreased the incidence of grade III/IV mucositis,
the need for total parenteral nutrition, and opioid an-
algesic use for mucositis compared to historic controls
in a cohort of patients with advanced hematologic ma-
lignancies who underwent TBI-based conditioning
and ASCT [36]. In a prospective randomized trial of
patients with multiple myeloma undergoing high-
dose melphalan followed by ASCT, amifostine de-
creased the incidence and severity of mucositis [37].
The recombinant human keratinocyte growth factor
palifermin was studied in 212 patients with hema-
tologic malignancies undergoing ASCT after condi-
tioning with TBI, etoposide, and cyclophosphamide.
The incidence of grade III/IV mucositis in patients
who received palifermin was 64% compared to 98%
in the placebo group; palifermin also reduced the dura-
tion of mucositis and the severity of patient-reported
symptoms [38]. Last, low-power laser therapy was
studied in a randomized, placebo-controlled trial in
38 patients with hematologic malignancies who were
undergoing either allogeneic or ASCT. Low-power
laser therapy resulted in a lower severity and shorter
duration of mucositis compared to placebo [39].
Thus, a number of potential interventions to reduce
mucositis could be studied in a population of patients
undergoing ASCT after BEAM conditioning. Further,
the addition of targeted agents or radioimmunoconju-
gates to the conditioning regimen may yield improved
outcomes without incurring additional toxicity.In summary, older patients with relapsed NHL
overall tolerated high-dose therapy with BEAM condi-
tioning and ASCT similar to their younger counter-
parts, with the exception of more frequent severe
mucositis and delayed recovery of platelet count to
.50,000/mm3 . Comorbid conditions were associated
with higher TRM and lower OS in this retrospective
cohort study. The decision to proceed with high-
dose therapy and autologous transplant in an older
patient should be individualized and incorporate
a careful assessment of comorbidities, functional sta-
tus, and renal function. Future studies prospectively
evaluating the association between comorbidities and
outcomes are warranted.
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